JPMorgan raised the firm’s price target on Ascendis Pharma (ASND) to $260 from $254 and keeps an Overweight rating on the shares. The firm remains “impressed” by Yorvipath’s sales trajectory following the Q2 report. The company sounds confident in Yorvipath’s U.S. reimbursement cycle time, the analyst tells investors in a research note. JPMorgan believes Ascendis is at an inflection point with “substantial” operating leverage ahead.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma Grants Employee Warrants to Foster Growth
- Ascendis Pharma A/S Q2 Earnings Call Highlights Growth
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
- Ascendis Pharma price target raised to $227 from $194 at TD Cowen
- Ascendis Pharma price target raised to $230 from $210 at RBC Capital